Literature DB >> 27084038

The role of innate immunity in the immunopathology and treatment of HBV infection.

Mala K Maini1, Adam J Gehring2.   

Abstract

In this review we give a brief update on sensors recently determined to be capable of detecting HBV, and examine how the virus represses the induction of pro-inflammatory cytokines like type I interferons. We overview cellular components of innate immunity that are present at high frequencies in the liver, and discuss their roles in HBV control and/or pathogenesis. We argue that many innate effectors have adaptive-like features or can exert specific effects on HBV through immunoregulation of T cells. Finally we consider current and possible future strategies to manipulate innate immunity as novel approaches towards a functional cure for HBV.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  HBV innate immunity; Innate immunotherapy; Innate sensors; Interferon-alpha; MAITs; MDSC; Monocytes; NK cells

Mesh:

Substances:

Year:  2016        PMID: 27084038     DOI: 10.1016/j.jhep.2016.01.028

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  52 in total

1.  The immunoglobulin γ marker 17 allotype and KIR/HLA genes prevent the development of chronic hepatitis B in humans.

Authors:  Danilo Di Bona; Janardan P Pandey; Anna Aiello; Massimo Bilancia; Giuseppina Candore; Calogero Caruso; Claudia Colomba; Giovanni Duro; Mattia Emanuela Ligotti; Luigi Macchia; Sergio Rizzo; Giulia Accardi
Journal:  Immunology       Date:  2019-11-12       Impact factor: 7.397

Review 2.  Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.

Authors:  Rohit Loomba; T Jake Liang
Journal:  Gastroenterology       Date:  2017-02-20       Impact factor: 22.682

3.  Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients.

Authors:  Chenliang Zhou; Chaofan Li; Guo-Zhong Gong; Shuang Wang; Ji-Ming Zhang; Dao-Zhen Xu; Li-Min Guo; Hong Ren; Min Xu; Qing Xie; Chen Pan; Jie Xu; Zhongyu Hu; Shuang Geng; Xian Zhou; Xianzheng Wang; Xiaoyu Zhou; Haili Mi; Gan Zhao; Wencong Yu; Yu-Mei Wen; Lihua Huang; Xuan-Yi Wang; Bin Wang
Journal:  Hum Vaccin Immunother       Date:  2017-06-30       Impact factor: 3.452

4.  Exosomes: multitask cargo carriers modulating innate immunity to viruses.

Authors:  Mario U Mondelli
Journal:  Cell Mol Immunol       Date:  2016-06-06       Impact factor: 11.530

Review 5.  Hepatitis B: Current Status of Therapy and Future Therapies.

Authors:  Elias Spyrou; Coleman I Smith; Marc G Ghany
Journal:  Gastroenterol Clin North Am       Date:  2020-03-29       Impact factor: 3.806

6.  An OX40/OX40L interaction directs successful immunity to hepatitis B virus.

Authors:  Jean Publicover; Anuj Gaggar; Jillian M Jespersen; Ugur Halac; Audra J Johnson; Amanda Goodsell; Lia Avanesyan; Stephen L Nishimura; Meghan Holdorf; Keith G Mansfield; Joyce Bousquet Judge; Arya Koshti; Michael Croft; Adil E Wakil; Philip Rosenthal; Eric Pai; Stewart Cooper; Jody L Baron
Journal:  Sci Transl Med       Date:  2018-03-21       Impact factor: 17.956

7.  A global scientific strategy to cure hepatitis B.

Authors:  Peter A Revill; Francis V Chisari; Joan M Block; Maura Dandri; Adam J Gehring; Haitao Guo; Jianming Hu; Anna Kramvis; Pietro Lampertico; Harry L A Janssen; Massimo Levrero; Wenhui Li; T Jake Liang; Seng-Gee Lim; Fengmin Lu; M Capucine Penicaud; John E Tavis; Robert Thimme; Fabien Zoulim
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-04-10

Review 8.  The cGAS-STING Pathway: Novel Perspectives in Liver Diseases.

Authors:  Dongwei Xu; Yizhu Tian; Qiang Xia; Bibo Ke
Journal:  Front Immunol       Date:  2021-04-29       Impact factor: 8.786

9.  Moving Fast Toward Hepatitis B Virus Elimination.

Authors:  Leda Bassit; Suzane Kioko Ono; Raymond F Schinazi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 10.  Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics.

Authors:  Shintaro Akiyama; Thomas G Cotter; Atsushi Sakuraba
Journal:  World J Gastroenterol       Date:  2021-05-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.